The Patterns of Conversion to Anti-Tuberculosis Drug Resistance in Mycobacterium tuberculosis
Keywords:
Anti-tuberculosis drug, Conversion to resistant, Drug susceptibility, Mycobacterium tuberculosis, TuberculosisAbstract
The prevalence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is increasing. We analyzed the patterns of drug resistance and the days of tracking period of acquiring anti-mycobacterial resistance. From January 2010 to December 2019, drug susceptibility tests (DST) were performed by the absolute concentration method using the Löwenstein-Jensen solid medium and pyrazinamidase activity test (to assess pyrazinamide resistance) in samples from patients who were referred to the Green Cross Laboratories in Yongin. Among the cases that showed resistance to one or more anti-tuberculosis drugs, 55 patients (33.1%) were resistant to isoniazid (INH) at the time of initial referral, and the rates for the development of resistant anti-tuberculosis drugs were ethambutol (EMB) (26.6%), rifampicin (RFP) (21.9%), quinolones (QUI) (21.9%) and pyrazinamide (PZA) (10.9%), in that order. In the cases sensitive to all 10 antituberculosis drugs initially, the development of resistance to INH was the most frequent, seen in 43 patients (7.2%). The average follow-up period was 435.6 days, and the resistance development was observed in the order of INH (7.2%), RFP (3.9%), SM (1.9%), QUI (0.7%), amikacin (AMK) (0.5%), and EMB (0.5%). The conversion of susceptible strains to resistant strains is an important warning sign for the patient, especially in cases of conversion to MDR or XDR. This information would help improve patient care during TB treatment.
References
GBD Tuberculosis Collaborators, 2018, The Global Burden of Tuberculosis: Results from the Global Burden of Disease Study 2015. Lancet Infect Dis, 18(3): 261–284. https://doi.org/10.1016/S1473-3099(17)30703-X
Korea Centers for Disease Control and Prevention. Annual Report on the Notified Tuberculosis Patients in Korea 2019, 2020, Seoul, 35–41.
Korea Centers for Disease Control and Prevention. Korean Guidelines for Tuberculosis (4th Edition), 2020, Seoul, 16–59.
Pablos-Méndez A, Raviglione MC, Laszlo A, et al., 1998, Global Surveillance for Antituberculosis-Drug Resistance, 1994–1997. N Engl J Med, 338: 1641–1649. http://doi.org/10.1056/NEJM199806043382301
Centers for Disease Control and Prevention (CDC), 2006, Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs – Worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep, 55(11): 301–305.
Velayati AA, Masjedi MR, Farnia P, et al., 2009, Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli: Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran. Chest, 136(2): 420–425. https://doi.org/10.1378/chest.08-2427
Espinal MA, Laszlo A, Simonsen L, et al., 2001, Global Trends in Resistance to Antituberculosis Drugs. N Engl J Med, 344: 1294–1303. http://doi.org/10.1056/NEJM200104263441706
Mitchison DA, 2005, Drug Resistance in Tuberculosis. Eur Respir J, 25: 376–379. https://doi.org/10.1183/09031936.05.00075704
WHO. WHO Treatment Guidelines for Drug Resistant Tuberculosis, 2016, World Health Organization, Geneva.
Lee K, Chong MS, 2021, The Patterns of Acquiring Anti-Mycobacterial Drug Resistance by Susceptible Strains of Mycobacterium tuberculosis. Korean J Clin Lab Sci, 53(2): 137–142. https://doi.org/10.15324/kjcls.2021.53.2.137
Son E, Jeon D, 2021, Current Situation of Tuberculosis and National Strategic Plan for Tuberculosis Control in Korea. J Korean Med Assoc, 64(4): 316–323. http://doi.org/10.5124/jkma.2021.64.4.316
Kim DH, Kim HJ, Park S-K, et al., 2008, Treatment Outcomes and Long-Term Survival in Patients with Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med, 178(10): 1075–1082. https://doi.org/10.1164/rccm.200801-132OC
World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008, 2008, Geneva.
Joint Committee for the Development of Korean Guideline for Tuberculosis, 2011, Korean Guidelines for Tuberculosis, 1st Ed. Korean Centers for Disease Control and Prevention, Cheongwon.
Kang YA, 2014, Diagnosis and Treatment of Multidrug-Resistant Tuberculosis. J Korean Med Assoc, 57(1): 27–33. http://doi.org/10.5124/jkma.2014.57.1.27
Van Deun A, Maug AKJ, Salim MAH, et al., 2010, Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med, 182(5): 684–692. https://doi.org/10.1164/rccm.201001-0077OC
Kim BJ, Lee IH, Lee DH, et al., 2006, The Current Status of Multidrug-Resistant Tuberculosis in Korea. Tuberc Respir Dis, 60(4): 404–411. https://doi.org/10.4046/trd.2006.60.4.404
WHO. Global Tuberculosis Report 2018, 2018, World Health Organization, Geneva.